Find below videos and webinars on myeloma. Click here to check full educational resources materials for all areas of work: myeloma and AL amyloidosis, access, patient evidence and capacity building and advocacy.
Mental Health and psychosocial support with myeloma

Now Playing
Mental Health and psychosocial support with myeloma
Surabhi Chaturvedi, Senior Psychotherapist and Service Lead, ...
Surabhi Chaturvedi, Senior Psychotherapist and Service Lead, Psychotherapy Service, Haemato-Oncology, King's College Hospital NHS Foundation Trust shares

Now Playing
Understanding cure in myeloma
What does “cure” look like in myeloma? Professor Philippe Moreau, ...
What does “cure” look like in myeloma?
Professor Philippe Moreau, President of the International Myeloma Society, and Head of Haematology at the University Hospital of Nantes, France explains the emerging ...concept of cure, why experts believe it is now appropriate to discuss it, and what it could mean for people living with myeloma.
He discusses how advances in treatment, particularly newer immunotherapies used alongside established approaches such as autologous stem cell transplantation, have dramatically improved patient outcomes. The conversation explores the proposed international consensus definition of a cure, including the importance of being off treatment and maintaining minimal residual disease (MRD) negativity for at least five years.
Professor Moreau also explains:
Why sustained MRD negativity is considered a key indicator of long-term disease control
Which treatment approaches may make a cure possible
Why access to the latest therapies varies between countries and affects patient outcomes
Which patients are currently most likely to achieve a cure
Why doctors emphasise hope while recognising that not every patient will achieve the same outcomes
The interview concludes by discussing how continuing advances in myeloma treatment are bringing life expectancy for some patients closer to that of the general population.
Please note: This interview reflects current expert opinion and emerging evidence. A cure is not yet achievable for everyone with myeloma, and treatment decisions should always be discussed with your healthcare team.
0:00 (Understanding cure in myeloma)
1:29 (Can we currently cure myeloma?)
2.51 (How are experts defining cure in myeloma?)
3:41 (Which treatments might help a cure?)
5:55 (Which patients could potentially be cured?)Show More
Professor Philippe Moreau, President of the International Myeloma Society, and Head of Haematology at the University Hospital of Nantes, France explains the emerging ...concept of cure, why experts believe it is now appropriate to discuss it, and what it could mean for people living with myeloma.
He discusses how advances in treatment, particularly newer immunotherapies used alongside established approaches such as autologous stem cell transplantation, have dramatically improved patient outcomes. The conversation explores the proposed international consensus definition of a cure, including the importance of being off treatment and maintaining minimal residual disease (MRD) negativity for at least five years.
Professor Moreau also explains:
Why sustained MRD negativity is considered a key indicator of long-term disease control
Which treatment approaches may make a cure possible
Why access to the latest therapies varies between countries and affects patient outcomes
Which patients are currently most likely to achieve a cure
Why doctors emphasise hope while recognising that not every patient will achieve the same outcomes
The interview concludes by discussing how continuing advances in myeloma treatment are bringing life expectancy for some patients closer to that of the general population.
Please note: This interview reflects current expert opinion and emerging evidence. A cure is not yet achievable for everyone with myeloma, and treatment decisions should always be discussed with your healthcare team.
0:00 (Understanding cure in myeloma)
1:29 (Can we currently cure myeloma?)
2.51 (How are experts defining cure in myeloma?)
3:41 (Which treatments might help a cure?)
5:55 (Which patients could potentially be cured?)Show More

Now Playing
MPE webinar | EHA 2026 highlights
Recording of the webinar given by Dr. Johan Lund, Department of ...
Recording of the webinar given by Dr. Johan Lund, Department of Medicine at Karolinska Institutet in Stockholm, Sweden, to explain the main myeloma and AL amyloidoisos highlights presented at the ...European Hematology Association (EHA) Annual Congress 2026.Show More

Now Playing
EHA 2026 CaMMouflage phase 1 clinical trial
Dr. Binod Dhakal, Medical College of Wisconsin, Milwaukee, USA talks ...
Dr. Binod Dhakal, Medical College of Wisconsin, Milwaukee, USA talks to MPE at EHA 2026 about the results of the phase 1 clinical trial known as CaMMouflage. This trial shows ...the safety and preliminary efficacy of the allogeneic anti-BCMA CAR T-cell therapy CB-011 in patients with relapsed or refractory myeloma.
0:00 (What our interview)
0:11 (What is CB-011?)
1:04 (About the CaMMouflage trial)
2:10 (Trial Results)
3:54 (What does this mean for patients?)Show More
0:00 (What our interview)
0:11 (What is CB-011?)
1:04 (About the CaMMouflage trial)
2:10 (Trial Results)
3:54 (What does this mean for patients?)Show More

Now Playing
EHA 2026 SUCCESSOR-2 clinical trial
MPE interviewed Dr. Alberto Orial, Institut Català d'Oncologia in ...
MPE interviewed Dr. Alberto Orial, Institut Català d'Oncologia in Germans Trias i Pujol Hospital, who explains the results of the late breaking abstract SUCCESSOR-2 evaluating mezigdomide, carfilzomib and dexamethasone (mezikd) ...vs carfilzomib and dexamethasone (kd) in relapsed/refractory myeloma.
0:00 (Watch our interview)
0:11 (What is mezigdomide)
1:00 (What is the SUCCESSOR-2 trial)
1:44 (What are the main results)
3:00 (What do these findings mean for relapsed/refactory myeloma patients)Show More
0:00 (Watch our interview)
0:11 (What is mezigdomide)
1:00 (What is the SUCCESSOR-2 trial)
1:44 (What are the main results)
3:00 (What do these findings mean for relapsed/refactory myeloma patients)Show More

Now Playing
EHA 2026 MONUMENTAL-3 clinical trial
MPE interviewed Dr. Albert Oriol, Institut Català d'Oncologia in ...
MPE interviewed Dr. Albert Oriol, Institut Català d'Oncologia in Germans Trias i Pujol Hospital, who explains the results of the MONUMENTAL-3 trial for relapsed/refractory myeloma patients, at EHA 2026.
0:00 (Watch ...now)
0:13 (What is talquetamab?)
1:16 (What is the MONUMENTAL-3 trial investigating and why?)
2:30 (What are the key results, including benefits and side effects?)
4:35 (What do these findings mean for relapsed/refactory myeloma patients?)Show More
0:00 (Watch ...now)
0:13 (What is talquetamab?)
1:16 (What is the MONUMENTAL-3 trial investigating and why?)
2:30 (What are the key results, including benefits and side effects?)
4:35 (What do these findings mean for relapsed/refactory myeloma patients?)Show More

Now Playing
MajesTEC-9 clinical trial
Dr. Cyrille Touzeau talks through the results from the phase III ...
Dr. Cyrille Touzeau talks through the results from the phase III MajesTEC-9 clinical trial and explains the benefits of teclistamab monotherapy compared with standard of care combinations in patients with ...relapsed or refractory myeloma.Show More

Now Playing
EHA2026 | EMN34 clinical trial
Dr. Cyrille Touzeau, University Hospital of Nantes, France, explains ...
Dr. Cyrille Touzeau, University Hospital of Nantes, France, explains for MPE, the results of the phase 2 ERASMM (EMN34) study, which evaluates safety and efficacy of elranatamab as early intervention ...in patients with high-risk smoldering myeloma.
0:00 (Watch now)
0:10 (What is elranatamab? How is it given and what should patients know about its current and potential uses?)
0:18 (What is the ERASMM (EMN34) trial investigating and what are its main results?)Show More
0:00 (Watch now)
0:10 (What is elranatamab? How is it given and what should patients know about its current and potential uses?)
0:18 (What is the ERASMM (EMN34) trial investigating and what are its main results?)Show More

Now Playing
Can you travel with multiple myeloma?
Can you travel with multiple myeloma? People living with myeloma still ...
Can you travel with multiple myeloma?
People living with myeloma still travel for work, family visits, or holidays. In this video, Dr Charlotte Pawlyn, Haematologist and Cancer Research UK Clinician, discusses ...some important things to consider before you travel to help you stay safe and enjoy your trip.
Topics covered include:
• speaking with your doctor or specialist nurse before travelling
• researching your destination, including vaccines, medical facilities, and emergency contacts
• planning medicines and treatments you may need when travelling
• getting travel insurance
• reducing your risk of infection while away
• knowing when to seek medical help
With some planning and simple precautions, many people with myeloma can continue to travel safely and enjoy their travel experiences.
Chapters
0:00 (Travelling with myeloma)
0:10 (What should someone with myeloma think about when planning a trip?)
1:43 (How can myeloma and its treatments affect infection risk when travelling and what simple precautions can help reduce it?)
3:14 (Before travelling abroad, what should patients know about vaccines, taking medicines and health risks in the country they are visiting?)
4:27 (During travel, what practical things can patients do to stay healthy?)
5:23 (What early signs should patients watch for, and when should they seek medical help?)Show More
People living with myeloma still travel for work, family visits, or holidays. In this video, Dr Charlotte Pawlyn, Haematologist and Cancer Research UK Clinician, discusses ...some important things to consider before you travel to help you stay safe and enjoy your trip.
Topics covered include:
• speaking with your doctor or specialist nurse before travelling
• researching your destination, including vaccines, medical facilities, and emergency contacts
• planning medicines and treatments you may need when travelling
• getting travel insurance
• reducing your risk of infection while away
• knowing when to seek medical help
With some planning and simple precautions, many people with myeloma can continue to travel safely and enjoy their travel experiences.
Chapters
0:00 (Travelling with myeloma)
0:10 (What should someone with myeloma think about when planning a trip?)
1:43 (How can myeloma and its treatments affect infection risk when travelling and what simple precautions can help reduce it?)
3:14 (Before travelling abroad, what should patients know about vaccines, taking medicines and health risks in the country they are visiting?)
4:27 (During travel, what practical things can patients do to stay healthy?)
5:23 (What early signs should patients watch for, and when should they seek medical help?)Show More

Now Playing
EYMPG webinar Mental health and emotional wellbeing
The European Young Myeloma Patients Group (EYMPG) on behalf of Myeloma ...
The European Young Myeloma Patients Group (EYMPG) on behalf of Myeloma Patients Europe hosted a webinar on mental health and emotional wellbeing. This lecture was given by Mitch Golant, PhD, ...Health Psychologist and Senior Consultant at Cancer Support Community, CA, USAShow More

Now Playing
ASH 2025 | IFM2021 01 trial
Dr.Salomon Manier, University of Lille, France, talks through this ...
Dr.Salomon Manier, University of Lille, France, talks through this teclestameb trial. This study shows that an “all-antibody–based” doublet regimen of teclistamab and daratumumab is highly effective and well-tolerated in elderly ...newly diagnosed myeloma patients.Show More

Now Playing
ASH 2025 | Cobra trial
COBRA is a clinical trial evaluating carfilzomib, lenalidomide and ...
COBRA is a clinical trial evaluating carfilzomib, lenalidomide and dexamethasone (KRd) versus bortezomib, lenalidomide
and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma (NDMM). Watch this interview with Dr. Dominik ...Dytfeld, lead author of this study that was presented in the American Society of Hematology (ASH), held in Orlando, Florida, US.Show More
and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma (NDMM). Watch this interview with Dr. Dominik ...Dytfeld, lead author of this study that was presented in the American Society of Hematology (ASH), held in Orlando, Florida, US.Show More

Now Playing
ASH 2025 | LINKER-MM4 trial
Dr. Xavier Leleu, Centre Hospitalier Universitaire de Poitiers, ...
Dr. Xavier Leleu, Centre Hospitalier Universitaire de Poitiers, France, explains the main results of the LINKER-MM4 clinical trial which evaluates safety and efficacy of linvoseltamab as a simplified monotherapy in ...first-line regimen in
newly diagnosed myeloma patients. The initial results of this study were presented at the American Society of Heamtology (ASH) Annual Congress, held in Orlando, Florida, US.Show More
newly diagnosed myeloma patients. The initial results of this study were presented at the American Society of Heamtology (ASH) Annual Congress, held in Orlando, Florida, US.Show More

Now Playing
ASH 2025 | UK MRA FiTNEss trial
The UK MRA FiTNEss trial aims to understand whether the International ...
The UK MRA FiTNEss trial aims to understand whether the International Myeloma Working Group (IMWG) frailty score can be used to tailor treatment according to a myeloma patient’s level of ...fitness. Dr. Charlotte Pawlyn, from The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, UK, explains the main results of this trial, which were presented at the American Society of Hematology 2025.Show More

Now Playing
ASH25 | Majestec-3 trial
Watch Dr. Charlotte Pawlyn from The Royal Marsden NHS Foundation Trust ...
Watch Dr. Charlotte Pawlyn from The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, UK, explain the main results of Majestec-3, one of the most important ...myeloma studies presented at the American Society of Hematology (ASH) Annual Congress in Orlando, Florida, US.Show More
1
of 11